Byondis Appoints Christoph Korpus, PhD, MBA, as Chief Business Officer
Byondis BV, an independent biopharmaceutical company dedicated to developing innovative, targeted medicines for cancer patients, has announced the appointment of Christoph Korpus, PhD, MBA, as its new Chief Business Officer (CBO). With more than 15 years of experience in the pharmaceutical industry, Dr. Korpus is expected to play a critical role in advancing the company’s pipeline of novel antibody-drug conjugates (ADCs) and monoclonal antibody-based therapeutics. His expertise in business development and strategic leadership will contribute to Byondis’ continued growth and success in the field of oncology.
Strengthening Leadership for Innovation in Oncology
Byondis is committed to the research and development of precision medicines that address unmet medical needs in oncology and autoimmune diseases. With a strong focus on innovation, the company integrates cutting-edge technology and scientific expertise to create targeted therapies that offer improved efficacy and safety for patients. The appointment of Dr. Korpus aligns with Byondis’ mission to expand its influence in the biopharmaceutical industry and bring groundbreaking treatments to market.
Jacques Lemmens, PhD, founder and CEO of Byondis, expressed confidence in Dr. Korpus’s ability to contribute significantly to the company’s vision.
“Christoph will play a pivotal role in advancing our pipeline of novel antibody conjugates and monoclonal antibody-based therapeutics in clinical development and leading Byondis’s business development efforts. With his strong strategic leadership skills, extensive experience in successfully collaborating with partners and building alliances, and his background in cancer drug development, Christoph will be a valuable addition to our leadership team,” Dr. Lemmens stated.
Dr. Korpus, who brings a wealth of experience in oncology drug development and pharmaceutical business strategies, is equally enthusiastic about his new role at Byondis.
“I am excited to bring my experience to Byondis and join such an innovative company dedicated to bringing hope to patients. I believe that Byondis, with its fully integrated research, development, and manufacturing capabilities, is uniquely positioned to deliver a new generation of antibody-drug conjugates (ADCs) and antibody-based therapies to cancer patients. I look forward to contributing to the company’s progress and growth,” said Dr. Korpus.
A Proven Leader in Oncology Drug Development and Business Strategy
Dr. Korpus joins Byondis after serving as the Director of Global Business Development and Licensing Oncology at Merck KGaA in Darmstadt, Germany. In this role, he was responsible for developing partnering strategies, negotiating oncology transactions, and leading cross-functional teams to establish collaborations with key industry stakeholders. His ability to drive strategic partnerships has contributed to the success of numerous oncology programs.
Throughout his tenure at Merck KGaA, Dr. Korpus played an instrumental role in driving cross-company innovation. His leadership in global commercial and development alliances enabled the execution of critical partnerships, fostering the development of promising oncology treatments. His strategic insights and negotiation skills have positioned him as a valuable asset in the pharmaceutical industry.
Dr. Korpus began his professional journey as a pharmacist after completing his pharmacy studies at Goethe University in Frankfurt am Main. He further advanced his academic credentials by earning a PhD from Ludwig Maximilian University of Munich and the University of Connecticut. Recognizing the importance of blending scientific expertise with business acumen, he pursued an MBA from the Kellogg School of Management at Northwestern University and the WHU-Otto Beisheim School of Management. His diverse educational background provides him with a unique perspective in bridging the gap between science and business in the biopharmaceutical sector.
Byondis: Pioneering Innovation in Targeted Therapies
Byondis has earned a reputation as a leading innovator in the biopharmaceutical industry, particularly in the field of antibody-drug conjugates (ADCs). ADCs represent a groundbreaking class of targeted therapies that combine the specificity of monoclonal antibodies with the potent cytotoxic effects of chemotherapy drugs. By delivering these cytotoxic agents directly to cancer cells, ADCs minimize damage to healthy tissues, thereby improving the therapeutic index of oncology treatments.
Byondis’ proprietary technology platforms enable the development of next-generation ADCs with enhanced efficacy and safety profiles. The company has successfully designed and optimized linker-drug technology, which improves the stability and targeted delivery of ADCs. By leveraging its expertise in antibody engineering and conjugation chemistry, Byondis continues to push the boundaries of ADC innovation.
Beyond ADCs, the company is actively engaged in the development of monoclonal antibodies (mAbs) and other biologic therapies aimed at addressing a broad range of cancers and autoimmune diseases. Byondis’ fully integrated research and development capabilities, coupled with its state-of-the-art manufacturing facilities, provide a strong foundation for the translation of scientific discoveries into clinical applications.
Expanding Business Development and Strategic Partnerships
With Dr. Korpus at the helm of business development, Byondis aims to strengthen its global partnerships and expand its commercial reach. His extensive experience in licensing, deal-making, and alliance management will be instrumental in identifying strategic opportunities that align with the company’s long-term vision.
The biopharmaceutical industry is highly competitive, and successful companies must navigate complex regulatory landscapes, secure funding for research and development, and establish strong collaborations to bring innovative therapies to market. Byondis recognizes the importance of strategic alliances and continues to seek partnerships that enhance its ability to develop and commercialize its pipeline of novel therapies.
Dr. Korpus’s expertise in oncology transactions and global business strategy will support Byondis in forming meaningful collaborations with pharmaceutical companies, research institutions, and investment partners. His leadership will be critical in driving the company’s growth and ensuring that its innovative treatments reach the patients who need them most.
Commitment to Transforming Cancer Treatment
Cancer remains one of the most significant global health challenges, with millions of patients diagnosed each year. Advances in targeted therapies, such as ADCs and monoclonal antibodies, have revolutionized cancer treatment by offering more precise and effective treatment options. Byondis remains committed to addressing the unmet needs of cancer patients through cutting-edge research and the development of next-generation therapeutics.
The appointment of Dr. Korpus underscores Byondis’ dedication to fostering innovation and leadership in oncology drug development. His strategic vision and industry expertise will play a vital role in advancing the company’s mission of delivering transformative medicines that improve patient outcomes.
About Byondis
Byondis is an independent, fully integrated biopharmaceutical research and development company developing innovative targeted cancer medicines to improve patients’ lives. The company develops new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics.
Byondis’s broad development portfolio encompasses preclinical and early-stage clinical programs. The product candidates combine Byondis’ expertise in linker drug technology (LD), antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development. Byondis’s expertise covers the entire preclinical research and development process, from early lead discovery to the production of clinical batches of the selected product candidates, all of which are conducted in-house.
The company employs a dedicated team of more than 300 people at its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands. For more information, visit www.byondis.com .
The original language in which the text is published is the official and authorized version. Translations are provided for clarity. Only the language version originally published is legally binding. Therefore, please compare translations with the original language version of the publication.
